At a glance
- Class: Dual GIP/GLP-1 receptor agonist peptide
- Evidence: High — phase 3 obesity/diabetes programs and approved indications
- Status: Approved prescription drug for specific indications.
What the evidence actually supports
This page separates established human outcomes from mechanistic, animal, observational, or anecdotal claims. A biological mechanism can justify research without proving a clinically meaningful benefit in healthy people.
Fitness and health relevance
LiftLab includes this compound because it is commonly discussed in metabolic health, recovery, endocrine physiology, body composition, or performance communities. Inclusion is not a recommendation to use it.
Safety and uncertainty
Peptides and peptide hormones can have systemic effects well beyond the desired target. Product purity, sterility, identity, dose accuracy, immunogenicity, endocrine feedback, glucose effects, blood pressure, fluid balance and drug interactions may matter depending on the compound. Unapproved online products add major quality-control uncertainty.
Research interpretation
When human trials exist, outcomes should be interpreted in the population and indication actually studied. Results from obesity, HIV lipodystrophy, endocrine deficiency, oncology, or other disease populations should not be assumed to translate to healthy recreational users.